RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation

Cancer Immunology Research

Volumn 5, Issue 6, 2017, Pages 455-467

  Engel, Christina ^a   Brügmann, Grethe ^a   Lambing, Silke ^a   Mühlenbeck, Larissa H ^a   Marx, Samira ^a   Hagen, Christian ^a   Horv, Dorottya ^a   Goldeck, Marion ^a   Ludwig, Janos ^a   Herzne, Anna Maria ^a   Drijfhout, Jan W ^b   Wenzel, Daniela ^c   Coch, Christoph ^a   Tuting, Thomas ^a,d   Schlee, Martin ^a   Hornung, Veit ^a,e   Hartmann, Gunther ^a   Van Den Boorn, Jasper G ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' TRIPHOSPHATE RNA; ALPHA INTERFERON RECEPTOR; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA INTERFERON; GLYCOPROTEIN GP 100; HYPOXIA INDUCIBLE FACTOR 1ALPHA; REACTIVE OXYGEN METABOLITE; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; UNCLASSIFIED DRUG; ANTIOXIDANT; RARRES3 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEDIFFERENTIATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMATIC REVIEW; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL LINE; CYTOLOGY; GENE KNOCKOUT; GENETICS; HYPOXIA; IMMUNOLOGICAL TOLERANCE; METABOLISM; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; HYPOXIA; IMMUNE TOLERANCE; MELANOMA; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; RECEPTORS, RETINOIC ACID; RNA; SPLEEN;

EID: 85020624688     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0129-T     Document Type: Article

References (43)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. BJR 1953;26:638-48.
2. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
3. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:1239-42.
4. Duan J-X, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008;51:2412-20.
5. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011;475:226-30.
6. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J-I, Cheng P, et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207:2439-53.
7. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012;22:725-36.
8. Aoshi T, Koyama S, Kobiyama K, Akira S, Ishii KJ. Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol 2011;1:226-32.
9. Goubau D, Deddouche S, Reis E Sousa C. Cytosolic sensing of viruses. Immunity 2013;38:855-69.
10. Schlee M, Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol 2016;16:566-80.
11. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009;31:25-34.
12. Beljanski V, Chiang C, Kirchenbaum GA, Olagnier D, Bloom CE, Wong T, et al. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. García-Sastre A, editor. J Virol 2015;89:10612-24.
13. Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, et al. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med 2016;22:807-11.
14. Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, et al. RIGI- like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8 T cells. Cell Death Differ 2014;21:1825-37.
15. Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, et al. Therapeutic efficacy of bifunctional siRNA combining TGF-b1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 2013;73:1709-20.
16. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 50 - triphosphate-siRNA: Turning gene silencing and Rig-I activation against melanoma. Nat Med 2008;14:1256-63.
17. Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in humanmelanoma cells. J Clin Invest 2009;119:2399-411.
18. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, et al. Antiviralimmunity via RIG-I-mediated recognition ofRNAbearing 5'- diphosphates. Nature 2014;514:372-5.
19. Goldeck M, Tuschl T, Hartmann G, Ludwig J. Efficient solid-phase synthesis of pppRNA by using product-specific labeling. Angew Chem Int Ed Engl 2014;53:4694-8.
20. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5'- Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7.
21. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'- phosphates. Science 2006;314:997-1001.
22. van den Boorn, JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity 2013;39:27-37.
23. UzeG, DiMarco S, Mouchel-Vielh E, MonneronD, Bandu MT, Horisberger MA, et al. Domains of interaction between alpha interferon and its receptor components. J Mol Biol 1994;243:245-57.
24. Schmid-Burgk JL, Schmidt T, Gaidt MM, Pelka K, Latz E, Ebert TS, et al. OutKnocker: A web tool for rapid and simple genotyping of designer nuclease edited cell lines. Genome Res 2014;24:1719-23.
25. Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, Latz E, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 2013;503:530-4.
26. Bhattacharya S, HuangFu W-C, Dong G, Qian J, Baker DP, Karar J, et al. Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene 2013;32:4214-21.
27. Keith B, Johnson RS, Simon MC. HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011;12:9-22.
28. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. Targeting hypoxic response for cancer therapy. Oncotarget 2016;7:13464-78.
29. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor- A chains activated by prolyl hydroxylation. EMBO J 2001;20: 5197-206.
30. Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1a-ZEB1 axis. Cancer Lett 2015; 359:107-16.
31. Shimojo Y, Akimoto M, Hisanaga T, Tanaka T, Tajima Y, Honma Y, et al. Attenuation of reactive oxygen species by antioxidants suppresses hypoxiainduced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis 2012;30:143-54.
32. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819-23.
33. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015.
34. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007;12:230-8.
35. Miles SL, Fischer AP, Joshi SJ, Niles RM. Ascorbic acid and ascorbate-2- phosphate decrease HIF activity and malignant properties of human melanoma cells. BMC Cancer 2015;15:237.
36. Tian W, Wang Y, Xu Y, Guo X, Wang B, Sun L, et al. The Hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity. J Biol Chem 2014;289:3339-51.
37. Serrano OK, Parrow NL, Violet P-C, Yang J, Zornjak J, Basseville A, et al. Antitumor effect of pharmacologic ascorbate in the B16murine melanoma model. Free Radical Biol Med 2015;87:193-203.
38. Kim HN, Kim H, Kong JM, Bae S, Kim YS, Lee N, et al. Vitamin C down-regulates VEGF production in B16F10 murine melanoma cells via the suppression of p42/44 MAPK activation. J Cell Biochem 2011;112:894-901.
39. Kang JS, Cho D, Kim Y-I, Hahm E, Yang Y, Kim D, et al. L-ascorbic acid (vitamin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway. Cancer Immunol Immunother 2003;52: 693-8.
40. Hahm E, Jin D-H, Kang JS, Kim Y-I, Hong S-W, Lee SK, et al. The molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma. J Cell Biochem 2007;102:1002-10.
41. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015;350:1391-6.
42. Tremante E, Santarelli L, Lo Monaco E, Sampaoli C, Ingegnere T, Guerrieri R, et al. Sub-apoptotic dosages of pro-oxidant vitamin cocktails sensitize human melanoma cells to NK cell lysis. Oncotarget 2015;6:31039-49.
43. Evdokimova V, Tognon CE, Sorensen PH. On translational regulation and EMT. Semin Cancer Biol 2012;22:437-45.